U.S., June 27 -- ClinicalTrials.gov registry received information related to the study (NCT07671534) titled 'Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors' on June 22.
Brief Summary: This is an open label phase II study using metronomic low-dose gemcitabine and mitomycin c given intravenously, and thalidomide administered orally, for patients with advanced solid tumors.
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Solid Tumor Cancer
Intervention:
DRUG: Gemcitabine
600 mg/m2 (Max: 1000 mg) i.v. on D1, D8, D15
DRUG: Mitomycin C
Mitomycin C 14 mg i.v. every 6 weeks
DRUG: Thalidomide
Thalidomide 100 mg daily x 15 days
Recruitment Status: RECRUITING
Sponsor: Sarcoma Oncology Re...